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Despite the constant exposure to genomic insults that 
may lead to malignancy, cancer is surprisingly a relatively rare 
occurrence, and this is largely credited to an elaborate network 
of endogenous tumor suppression. Many effectors of tumor 
suppression have been identified, and their functions when acti-
vated in damaged cells have in large part been elucidated. What 
is less clear is whether there are common target gene(s) of tumor 
suppression, whose expression must be ablated in order to block 
transformation and preserve cellular homeostasis. Fresh experi-
mental evidence suggests that silencing of the mitotic regulator 
and cell death inhibitor, survivin, is a universal requirement for 
successful tumor suppression in humans.
Survivin is the smallest member of the Inhibitor of Apoptosis 
(IAP) gene family.1 Originally described as cell survival factors 
that target caspases, we now know that IAPs have a much broader 
portfolio of functions, encompassing signaling pathways, cell divi-
sion, metabolism and adaptation to unfavorable environments.1 
Survivin embodies this multifunctional diversity, and compelling 
data accumulated over a decade have elucidated many of its essen-
tial roles as a regulator of mitosis, a broad cytoprotective factor, and 
an effector of cellular adaptation to stress.2 These disparate func-
tions rely on hosts of regulated interactions that involve survivin 
and multiple protein partners, including tubulin and various chro-
mosomal passenger proteins in the control of mitosis, other IAP 
family members to counteract apoptosis, and Heat Shock Proteins 
in the modulation of the cellular stress response.2
These ‘survivin networks’ are dramatically exploited in cancer, 
and survivin is unanimously viewed as one of the most prominent 
cancer genes.2 Overexpressed in virtually every human tumor, but 
undetectable or present at very low levels in most normal adult 
tissues, survivin expression has been consistently associated with 
disease progression, metastatic dissemination, resistance to therapy 
and death from disease.3 Although not a canonical drug target, 
efforts to disable the survivin networks for novel cancer therapeu-
tics have now reached the clinic, and some encouraging responses 
have been noted in early clinical trials.2,3
Because of the intrinsic interest in survivin biology, and 
the potential clinical benefits of survivin-directed therapeutics, 
extensive efforts have been devoted to understand how survivin 
becomes so sharply differentially expressed in tumors, compared 
to most normal tissues. From these studies, a prevailing consensus 
has emerged that a ‘tumor-specific’ expression of survivin2 is 
predominantly dictated at the level of transcription, and that 
survivin gene expression may be globally ‘deregulated’ in tumors, 
in vivo. Accordingly, survivin promoter activity is basically silent 
in normal cells, but strongly expressed in tumor cells,4 and this 
occurs independently of cellular heterogeneity, mitotic status, or 
genetic makeup. The differential expression of the survivin gene 
in normal versus tumor cells is so dramatic that therapeutic strate-
gies to drive tumor-specific expression of suicidal genes under the 
control of the survivin promoter have now advanced to preclinical 
stages in a number of settings.5,6 Supporting this model, comple-
mentary studies identified a number of oncogenic gene expression 
pathways, for instance initiated by activated STAT3,7 NFκB8 
and potentially, Myc,9 that converge on the survivin promoter to 
stimulate vigorous transcription selectively in tumor cells (Fig. 1). 
Developmental gene expression pathways exploited in tumorigen-
esis, for instance Notch10 or Wnt/β catenin11 also earmark the 
survivin gene for differential expression in transformed cells (Fig. 
1). Available evidence suggests that these mechanisms are direct, 
and discrete binding sites for various oncogenic transcriptional 
activators, including NFκB, STAT3, Notch and TCF4/β-catenin 
have been identified in the proximal survivin promoter.
Although there is little doubt that oncogene signaling activates 
survivin gene transcription, this is likely not the whole story. 
Evidence independently contributed by several laboratories seems 
to point to a reciprocal hypothesis, that it is not only the expression 
of oncogenes, but also the loss of tumor suppressors programmed 
to silence the survivin gene that is responsible for the differential 
expression of survivin in cancer, in vivo (Fig. 1).
In support of this model, pioneering studies of Hoffman and 
colleagues,12 and Mirza and colleagues13 identified survivin as 
one of the relatively few known genes that is actively repressed 
by wild type p53. These studies were universally confirmed by 
others, discrete p53-resposive elements in the proximal survivin 
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promoter were identified, and monitoring survivin levels is now a 
routine functional assay to test for wild type p53 activity in cells. 
In independent experiments, the Altura laboratory found that the 
retinoblastoma protein (Rb), another pivotal tumor suppressor 
controlling the G1/S transition of the cell cycle, also acutely 
silenced survivin gene expression.14 This pathway was also direct in 
that E2F transcription factors (E2F1, E2F2 and E2F3) intercalated 
in the Rb pathway bound to discrete sites in the survivin promoter, 
and repressed its transcription. Other groups independently vali-
dated this model, and a role of Rb/E2F in shutting off survivin 
gene transcription is now viewed as one of the mechanisms that 
keep survivin levels low in interphase cells. In addition, the 
Adenomatous Polyposis Coli (APC) protein, a tumor suppressor 
almost invariably lost in colorectal cancer, and the Fragile Histidine 
Triad (FHIT) gene, a fragile site with tumor suppressive functions, 
have also been shown to repress survivin levels, in vivo.15,16 The 
mechanism(s) of these responses have not been completely eluci-
dated, but it seems likely that both pathways silence the survivin 
gene directly, potentially via modulation of Akt16 or β-catenin/
TCF-4,17 binding to the proximal survivin promoter. And finally, 
Wang and colleagues linked inhibition of survivin gene expression 
to one of the main tumor suppression networks in breast and 
ovarian cancer, i.e., BRCA1.18 This pathway relied on a complex 
transcriptional network in which BRCA1 bound to the promoter 
of SIRT1, a NAD-dependent class III histone deacetylase, and 
stimulated its de novo transcription. In turn, the newly produced 
SIRT1 bound to the proximal survivin promoter shutting off 
transcription via epigenetic chromatin modifications involving 
histone H3.
Altogether these results prompted a broad, but testable exper-
imental question: is survivin a common target of multiple 
tumor suppression networks in humans? Recent studies from 
our group tried to address this question by looking at the PTEN 
pathway, which is arguably one of the most mutated tumor 
suppressor networks in human cancer.19 The Phosphatase and 
Tensin homolog deleted from chromosome Ten (PTEN) is a dual 
specificity phosphatase that controls cell proliferation, cell survival 
and cell size by removing the D3 phosphate from the lipid second 
messenger phosphatidylinositol triphosphate. Two of the critical 
targets of PTEN are the Akt and PDK1 kinases, and shutting off 
their signaling responses interrupts growth factor-initiated cell 
proliferation, maintains chromosomal integrity, and further ampli-
fies p53-mediated tumor suppression.20
Against this backdrop, Guha and collaborators found that 
forced expression of PTEN suppressed survivin levels in tumor 
cell types, whereas, knocking down PTEN in PTEN wild type 
tumor cells resulted in increased survivin expression.21 As seen 
before with other tumor supressors, PTEN expression acutely 
silenced transcription of the survivin gene, and this response 
involved a 1,430 nt segment of the proximal survivin promoter.21 
But how does PTEN do this? To answer this question, Guha et al. 
focused on Forkhead transcription factors of the FOXO subfamily, 
which function as potential effectors of PTEN signaling,22 and 
were previously implicated in modulating survivin gene expres-
sion in endothelial cells.23 In the study by Guha et al. siRNA 
gene silencing or dominant negative interference of FOXO1 or 
FOXO3a increased endogenous survivin levels in tumor cells.21 
This was a direct transcriptional response as FOXO1 and FOXO3a 
bound to discrete sites in the proximal survivin promoter, shutting 
off gene expression in tumor cells. As expected from the role of 
survivin in tumor maintenance, PTEN-induced downregulation of 
survivin increased apoptosis in tumor cells, in a reaction reversed 
by re-expression of recombinant survivin.21 There was also prelimi-
nary evidence that this regulatory circuitry was operative in vivo, 
as expression of survivin and PTEN turned out to be inversely 
correlated in patient series of glioblastoma and colon cancer, and 
conditional deletion of PTEN in the mouse prostate resulted in 
increased survivin expression, before emergence of full blown 
epithelial dysplasia.21 Almost at the same time, an independent 
study also reported that FOXO3 signaling silenced survivin gene 
expression in neuroblastoma models,24 thus similar to the findings 
of Guha et al.21
Is there a common thread that links these studies? And, if so, 
what are their broader implications? First, it is now apparent that 
targeting survivin is a general property of the intrinsic tumor 
suppression machinery (Fig. 1). Although using different path-
ways, effectors and DNA recognition sequences, all of the best 
characterized tumor suppression networks in humans12-16,18,21,24 
share the same target gene, survivin, and efficiently silence its 
transcription (Fig. 1). This leads to a general model that acute 
lowering of survivin levels may be an indispensable prerequisite 
to effectively antagonize cellular transformation in humans. In 
this context, targeting survivin may provide a unique advantage 
to oppose transformation, by simultaneously disrupting multiple 
downstream networks of cell proliferation, cytoprotection and 
adaptive resistance to unfavorable environments.2 By extension, 
genomic surveillance by multiple tumor suppressor pathways may 
contribute to maintain low levels of survivin in normal cell types, 
a straightforward model to explain the differential distribution of 
survivin in tumor versus normal tissues, in vivo.2 Experimental 
evidence in transgenic mice seems consistent with this possibility, 
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Figure 1. Oncogene and tumor suppressor networks targeting the survivin 
pathway. See text for details.
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and has implicated wild type p53 as a pivotal repressor of the 
survivin gene in most normal adult tissues, in vivo.25
As a corollary argument, these data broaden the traditional 
model of oncogene-directed survivin gene expression, and suggest 
that loss of one or more tumor suppressor(s) via inactivating 
mutations and/or loss of heterozygosity may be just as critical to 
de-repress transcription of the survivin gene, and contribute to its 
invariably elevated levels in tumor cells (Fig. 1). Because of the 
generality of this combined process (Fig. 1), one may tentatively 
conclude that deregulation of the survivin networks, uncoupled 
from tumor suppressors, may be required early to initiate the 
process of malignant transformation, and later to maintain the 
malignant phenotype of established tumors.2 Consistent with this 
model, survivin levels are highly elevated in premalignant lesions, 
for instance of the skin26 or colonic mucosa,27 suggesting that 
these changes occur early in tumorigenesis, and therapeutic inter-
ference with the survivin networks in established tumors cannot be 
compensated for, and results in apoptosis, proliferative arrest and 
sensitization to cell death or stress stimuli.2
In summary, recent evidence from various laboratories, including 
our own, have shown that survivin is a universal target of intrinsic 
tumor suppression networks. Several questions remain to be 
answered to position these pathways in their proper pathophysi-
ological context. For instance, is there a preferential aspect of 
the multiple functions of survivin in cell division, cytoprotection 
or adaptation that must be absolutely suppressed to antagonize 
malignancy? Preliminary evidence from transgenic mice suggest 
that it is the cell cycle-independent, potential anti-apoptotic and 
adaptive functions of survivin that are predominantly exploited in 
tumorigenesis,25 but whether the same is true upon loss of tumor 
suppressor(s) remains to be elucidated. And what is the interplay, 
if any, between the disparate tumor suppressor networks that 
converge on the survivin gene? Given the fast pace of survivin 
research, the answer to some of these questions, and additional 
ones posed by the new results, will certainly be forthcoming. 
Regardless, the novel signaling circuitries between survivin gene 
regulation and tumor suppression further highlights the pivotal 
and perhaps indispensable role of the survivin networks in cellular 
transformation and tumorigenicity. This bodes well for the further 
development of survivin-based therapeutics, which would be 
expected to mimic the reintroduction of tumor suppressor mecha-
nisms, potentially removing an essential requisite to maintain the 
malignant phenotype, in vivo.2
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